U.S. antitrust regulators might not attempt to block CVS Health's proposed $68 billion takeover of Aetna, according to Bloomberg, which cites a report by Reorg Research.
The report had positive effects on the companies' shares, although Reorg Research did not disclose the origin of the information. CVS stock spiked 3.1 percent July 12, and Aetna shares increased 2.3 percent the same day.
According to Reorg Research, Justice Department staff are expected to OK the deal. The Justice Department will make their recommendation to senior officials, who will issue a final ruling by the end of July, according to Bloomberg's analysis of the report.
Neither CVS nor Aetna responded to Bloomberg's request for comment.
More articles on transactions and valuations:
Cleveland Clinic makes foray into China
9 private equity firms vied for Envision before KKR deal: 3 things to know
Beth Israel, Lahey merger faces pushback from attorney general